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13 miRNAs were upregulated and 17 downregulated in 
migrating cells compared to corresponding spheroids. The 
three most deregulated miRNAs, miR-1227 (up-regulated), 
miR-32 (down-regulated) and miR-222 (down-regulated), 
were experimentally overexpressed. A non-significantly 
increased migration rate was observed after miR-1227 
overexpression. A significantly reduced migration rate was 
observed after miR-32 and miR-222 overexpression. In 
conclusion a shift in microRNA profile upon glioma cell 
migration was identified using an assay avoiding serum-
induced migration. Both the miRNA profiling and the func-
tional validation suggested that miR-1227 may be associ-
ated with increased migration and miR-32 and miR-222 
with decreased migration. These miRNAs may represent 
potential novel targets in migrating glioma cells.
Keywords Glioblastoma · Migration · Serum-free · 
MicroRNA · Target
Introduction
Glioblastoma multiforme (GBM) is the most common and 
malignant primary brain tumor in adults. Despite multi-
modal treatment options including surgery, radiation and 
chemotherapy, patients with GBM have an overall poor 
outcome with a mean survival of 14.6 months [1] and a 
5-year survival rate of 9.8% [2]. Gliomas are highly inva-
sive and migrate into the normal brain parenchyma along 
vessels and white matter fiber-tracts [3]. Therefore, migrat-
ing tumor cells will always be left behind despite surgery. 
The underlying phenotype characterizing highly aggres-
sive migrating tumor cells causing short survival and 
treatment failure is not yet fully understood. As cancer 
stem cells (CSCs) have been shown to be both radio- and 
Abstract Glioblastoma multiforme (GBM) is the most 
frequent malignant primary brain tumor. A major reason 
for the overall median survival being only 14.6 months is 
migrating tumor cells left behind after surgery. Another 
major reason is tumor cells having a so-called cancer 
stem cell phenotype being therefore resistant towards 
traditional chemo- and radiotherapy. A group of novel 
molecular targets are microRNAs (miRNAs). MiRNAs 
are small non-coding RNAs exerting post-transcriptional 
regulation of gene expression. The aim of this study was 
to identify differentially expressed miRNAs in migrat-
ing GBM cells using serum-free stem cell conditions. We 
used patient-derived GBM spheroid cultures for a novel 
serum-free migration assay. MiRNA expression of migrat-
ing tumor cells isolated at maximum migration speed 
was compared with corresponding spheroids using an 
OpenArray Real-Time PCR System. The miRNA profiling 
revealed 30 miRNAs to be differentially expressed. In total 
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chemoresistant [4, 5], this may explain part of the resist-
ance of migrating glioma cells.
Mature microRNAs (miRNAs) are short single-stranded 
non-coding RNAs involved in post-transcriptional regu-
lation of numerous different target messenger RNAs 
(mRNAs). The miRNAs are key regulators, reported to reg-
ulate up to 60% of all mammalian genes [6, 7]. In GBMs 
several over-expressed miRNAs have been identified [8, 
9] and inhibition of some of these diminish cellular prolif-
eration rates [10–12] and angiogenesis [12]. This suggests 
novel therapeutic possibilities in the treatment of GBM.
Using different migration assays, numerous groups have 
identified several miRNAs associated with migration or 
invasion [9–13]. However, all employed migration assays 
have been performed with the use of fetal calf serum in the 
culture medium. Because fetal calf serum influences the 
tumor cell phenotype [14–16] and may influence expres-
sion of miRNA involved in migration the use of a recently 
developed serum-free migration assay was preferred [17].
The aim of this study was to discover novel miRNAs 
associated with GBM tumor cell migration. Five GBM 
spheroid cultures with tumorigenic stem-like cells were 
used, three previously established in our group [18–20] 
and two established as a part of the present study. To iso-
late migrating cells from non-migrating GBM cells at opti-
mal time-points with fast migration, we used a flat surface 
migration assay allowing easy monitoring and isolation 
of migrating GBM cells. We recently established such an 
assay using serum-free so-called stem cell medium in an 
attempt to allow migrating cells to preserve a potential can-
cer stem cell phenotype [17]. MiRNA profiling was per-
formed on the migrating cells and corresponding spheroids 
to identify deregulated miRNAs. In addition, we func-
tionally evaluated the effect of experimental over-expres-
sion of the three most deregulated miRNAs in relation to 
migration.
Materials and methods
Culturing of cells
Five different GBM spheroid cultures were utilized 
[18–20]. Three were previously established in our group 
(T78, T86, T87) [18–20] and two were established as a 
part of the present study (T111, T113). These cultures 
have the ability to form new spheroids at clonal den-
sity, have a karyotype typical of GBMs and the abil-
ity to differentiate into cells expressing neuronal, astro-
cytic and oligodendrocytic markers upon culturing in 
fetal calf serum medium, as well as the ability to form 
highly invasive tumors upon orthotopic xenografting 
(Fig.  1). The GBM spheroid cultures and recombinant 
U251 cells transfected with miRNA constructs were 
grown as free-floating spheroids in serum-free medium 
[18–20]. The serum-free medium contained Neurobasal 
A (Life Technologies), 1% B27 without vitamin A (Life 
Technologies), 0.5% N2 (Life Technologies), 1% Peni-
cillin–streptomycin (Life Technologies), 1% Glutamine 
(Life Technologies), 25  ng/mL EGF(Epidermal Growth 
Factor) (Sigma Aldrich), 25  ng/mL bFGF (basic Fibro-
blast Growth Factor) (Trichem). All cultures were kept 
at 36 °C and 5%  CO2. Permission to use tumor tissue 
was given by the Regional Scientific Ethical Committee 
(approval number S-VF-20040102). Tissue was obtained 
after informed consent.
The commercial cell line U251 was used for miRNA 
transfection, since in our experience the patient-derived 
cultures are difficult to transfect. These cultures are more 
patient-like but on the other hand also most likely poly-
clonal and more heterogeneic to work with.
Migration assay
The migration assay used was established in a recently 
published parallel study [17], where all five GBM spheroid 
cultures were included and characterized with respect to 
migration distance and migration speed. This flat surface 
migration assay allowed monitoring of cell migration and 
easy isolation of migrating cells for further analysis. Each 
well, in a 12 well plate, was coated with a mixture of Gel-
trex (Gibco) and serum-free medium (1:49) and incubated 
at 36 °C and 5%  CO2. The supernatant was removed the fol-
lowing day and a single spheroid was isolated and placed 
in each coated well. Afterwards one ml serum-free medium 
was added to each well and incubated at 36 °C and 5%  CO2. 
For comparison of the commercial cell line U251 used 
for the transfection studies to the five GBM spheroid cul-
tures, time-lapse microscopy was performed at 36 °C and 
5%  CO2, with pictures taken every hour for 5 days in all 
five GBM spheroid cultures including. From the time-lapse 
microscopy images we measured and calculated migration 
distance and speed using ImageJ, an open source program. 
Migrating cells and corresponding spheroids were isolated 
at the time point of highest migration speed in a new set 
of experiments. The non-migrating cells still shaped as a 
spheroid were removed under a microscope with a micropi-
pette where after the residual migratory cells were isolated 
after 48  h of migration. Cells were then placed in Trizol 
(Life technologies) and vortexed to ensure lysis of cells. 
Finally they were frozen before miRNA profiling was done.
The migration assay was upon miRNA transfection per-
formed in duplicate with a 12 well plate in each experi-
ment. Doxycycline was used to activate the over-expression 
of the transfected miRNA.
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Fig. 1  Characterization of patient-derived GBM spheroid cultures. 
The two GBM spheroid cultures established (T111 and T113) were 
cultured in serum-free medium as spheroids which upon trypzina-
tion to single cells developed new spheroids (a). The spheroid cul-
tures were karyotyped and common characteristics were found such 
as gain of chromosome 7, found in both spheroid cultures, and loss of 
chromosome 10 (only T111) (b). Large tumors with highly migratory 
capacity upon orthotopic xenografting were formed (c). A differentia-
tion assay was performed showing expression of the astrocytic marker 
GFAP (d–f) and the neuronal marker MAP2 (g–i). The MGMT status 
for both GBM spheroid cultures were performed with a pyrosequenc-
ing assay. T111 was found to be methylated and T113 to be unmethyl-
ated. Both were derived from IDH1 wild type tumors, representing 
primary GBMs. The molecular subtype based on mRNA profiling 
revealed T111 as mesenchymal and T113 as classical. An overview 
of MGMT, mIDH1 and subtype status of T111 and T113 and the 
three remaining spheroids cultures is given in (j). All illustrations are 
shown for T111. Scalebar in a 100 µm, c 2.5 mm and d–i 100 µm
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MicroRNA profiling
After thawing, chloroform at 20% volume was added to the 
cells to ensure proper lysis. Total RNA was purified from 
migrating spheroids (40 × 12 well plates) and correspond-
ing free floating spheroids according to the manufactures 
protocol using the miRNeasy Mini Kit (Qiagen). Total 
RNA concentration was determined by Ribogreen [21] and 
samples were dried down in a speedy vac to suitable vol-
ume. A concentration of 30 ng/μl was used for Open Array 
Analysis. Four μl of RNA extract was used as sample input 
for miRNA profiling on the OpenArray® Real-Time PCR 
System (based on miRBase v. 14 database which detect 
more than 700 miRNAs) using the manufacturer’s instruc-
tions (Applied Biosystems, Life technologies, Carlsbad, 
CA). For cultures, where more RNA extract than 4 µl was 
available, the extra material was used for extra replicates. 
Briefly, Megaplex™ RT Primers, Human Pool A v.2.1 and 
Megaplex™ RT Primers, Human Pool B v.3.0 were used 
for the reverse transcription step. Megaplex™ PreAmp 
Primers, Human Pool A v.2.1 and Megaplex™ PreAmp 
Primers, Human Pool B v3.0 were used for the PreAmp 
step.
Bioinformatic analysis on microRNA data
OpenArray® miRNA profiling data were processed and fil-
tered using Perl and R scripts. Briefly, pre-filtering of data 
was performed to include only reliable Amp Scores (>1.15) 
and ΔCts in the range of 10–28. ΔCts above or below the 
range were considered unreliable, and hence “undetected”. 
Further analyses were done in R (http://www.R-project.
org). Global mean normalization was used to normal-
ize across samples. Paired differential expression analysis 
of miRNA expression between migrating cells and corre-
sponding spheroids was done in the Bioconductor pack-
age limma for R (http://www.bioconductor.org). Benjamini 
and Hochberg’s method [22] to control the false discovery 
rate (FDR) was utilized to adjust the p-values for multiple 
testing.
Cloning of the synthetic miRNA constructs
The synthetic miRNA constructs from the top three upreg-
ulated and top three downregulated miRNAs followed the 
Life-technologies algorithm for miRNA embedded short 
hairpin RNA (shRNA) expression. It uses the regula-
tory sequences of the murine miR-155. The design of the 
sequences was done according to miRBase 21 annotation as 
described by Hou et al. [23] as well as chemically synthe-
sized as approximate 65-mer DNA oligos (MWG-Biotech, 
Eurofins). Top strand and bottom strand were annealed to 
form a double stranded DNA fragment with sticky ends and 
ligated into the linearized pcDNA™ 6.2-GW/miR vector 
(Invitrogen) with compatible overhangs. The EmGFP-miR-
neg Control construct (Invitrogen) was used as negative 
control. The integrity of the constructs were confirmed by 
sequencing with M13 primers and transferred via Gateway 
cloning into the pDest1a expression vector which drives the 
expression of the miRNA constructs under the control of 
a tetracycline inducible cytomegalovirus (CMV) promoter 
[24].
Transfection of cells with plasmid DNA
Cells were seeded at a density of 6.5 × 104 cells per well 
in 6-well plates. The next day medium was replaced with 
fresh growth medium (DMEM medium supplemented 
with 10% fetal calf serum, 2mM l-Glutamine and 100 µ/
mL Pen-Strep) and the expression plasmids co-transfected 
with pOG44 plasmid using GeneJammer transfection rea-
gent. After 48  h of incubation, the medium was changed 
with selection medium containing 250 µg/ml hygromycin. 
The medium was exchanged 2–3 times per week and non-
green fluorescent colonies expanded as individual recom-
binants. Thereafter the medium was changed to serum-free 
medium. Cells were cultured as free floating spheroids and 
passaged 5 times until the migration assay was performed.
Since the recombinant cell lines contain the respec-
tive miRNA constructs under the control of a tetracycline 
inducible promoter, 50 ng/ml Doxycycline (Life Technolo-
gies™) was added to the medium 48 h before experiments 
were conducted to activate the expression of the miRNA 
constructs. MiRNA transfection to U251 was performed 
twice.
The migration distance was measured for 48 h after start 
of the migration assay since the highest migration speeds 
were seen within the first 48 h.
Real-time PCR
Total RNA extraction was performed with RNeasy Mini 
Kit (Qiagen) including On-column DNase Digestion with 
RNase-Free DNase set (Qiagen). Prior to processing, 
sample RNA concentration was measured using a Nan-
odrop™ 2000 (Thermo Scientific). Changes in expression 
of miR-32 ± Doxycycline, miR-222 ± Doxycycline and 
miR-1227 ± Doxycycline were evaluated using TaqMan 
microRNA RT kit and Megaplex RT Primers (Life Tech-
nologies™) and miRNAs were pre-amplified using 
TaqManPreAmp Master mix and PreAmp Primer Pools, 
Human Pools Set v3.0 (Life Technologies™); reverse-
transcription and pre-amplification were performed with 
the thermocycler GeneAmp PCR system 9700 (Life Tech-
nologies™) using the protocol for low sample input from 
the manufacturer (http://www.tools.lifetechnologies.com). 
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MiRNA quantification was performed by Real-Time PCR 
using the standard protocol of TaqManOpenArray Human 
miRNA Panel and the QuantStudioTM 12  K Flex Real-
Time PCR System (Life Technologies™). Hsa-miR-16 
was used for normalization. All reactions were performed 
in duplicates. Data was analyzed in Biogazelle qBase + ver. 
3.0. Exclusion criteria were the following: Cq confidence 
lower than 0.8, Ct standard deviation in replicate group 
higher than 0.5, no amplification (amplification algorithm 
results lower than 0.1), noise spikes (spikes algorithm 
results higher than 1) and Ct higher than 32.
Statistical analysis
Comparisons of miRNA profiling were performed using 
Benjamini and Hochberg’s analysis. Comparison of 
miRNA expression and migration distance were performed 
with student’s t-test. Statistical significance was considered 
at p < 5%.
Results
The original U251 cell line was capable of migration 
reaching a distance and speed similar to the five GBM 
spheroid cultures earlier characterized [17]. The serum-
free migration assay combined with time-lapse micros-
copy revealed continued migration for a duration of 5 
days (Fig. 2a). A maximum migration speed was reached 
after 18 h for all cultures except the T87 GBM spheroid 
culture, which reached a maximum after 48 h (Fig.  2b). 
The time-point of highest migration-speed was inter-
esting based on an assumption that miRNAs related to 
migration would be most deregulated when cells were 
migrating at maximum speed. The miRNA profiling of 
all five GBM spheroids and their corresponding migrat-
ing cells revealed 30 significantly deregulated miRNAs 
(Table 1). In total 13 miRNAs were found to be upregu-
lated and 17 downregulated in the migrating cells com-
pared to the levels found in the corresponding spheroids. 
Fig. 2  Migration time-lapse microscopy showing results for the five 
GBM spheroid cultures and the U251 cell line. Migration distance 
was measured for all spheroid cultures and U251 over five days (a). 
Migration speed was calculated for each spheroid culture and the 
U251 cell line (b). Migration data for the GBM spheroid cultures 
were obtained in a separate study and included here for comparison 
[17]. The miRNA profiling of isolated migrating cells and corre-
sponding spheroids revealed a clustering of significantly deregulated 
microRNAs in both migrating and corresponding spheroids (c). The 
volcano plot illustrates the microRNA deregulation pattern in migrat-
ing cells (d). Data are shown as means ± SEM, n = 22 for each sphe-
roid culture or cell line
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Three miRNAs (miR-1227, miR-483-5p and miR-886-3p) 
were found to be more than twofold upregulated in the 
migrating cells. Three miRNAs (miR-32,miR-222 and 
miR-29b) were more than threefold downregulated in 
the migrating cells. The heatmap from the miRNA pro-
filing revealed a separate clustering of migrating cells 
and corresponding spheroids. The heatmap was based on 
miRNAs being significantly deregulated after multi-
ple testing (Fig.  2c). Interestingly the T87 GBM sphe-
roid culture, the only of Proneural subtype—revealed 
a clustering of migrating cells with the corresponding 
spheroids (Fig. 2c). The volcano plot shows distribution 
of these miRNAs (Fig. 2d).
Transfection of the top three and bottom three deregu-
lated miRNAs was successfully achieved for miR-1227, 
miR-32 and miR-222. Although transfections were per-
formed twice a successful transfection of miR-483-5p and 
miR-29b could not be achieved. The miR-886-3p was at 
the time of transfection no longer determined as a miRNA 
according to the miRBase v. 21 (http://www.miRBase.org). 
Thus miR-886-3p was omitted from the study.
When qPCR results were normalized to miR-16 there 
was an increased miR expression after induced overexpres-
sion of miR-1227 (2.4 fold) (Fig.  3a), miR-32 (2.6 fold) 
(Fig. 3b) and miR-222 (3.8 fold) (Fig. 3c).
Upon induced overexpression of miR-1227 in U251 
cells, a 1.2-fold increase in migration distance was meas-
ured after 48  h, although it was not statistical significant 
(Fig.  4a–c). Upon induced overexpression of miR-32, a 
0.45-fold significant decrease in migration distance was 
measured (Fig.  4d–f). Upon induced overexpression of 
miR-222 (Fig.  4g–i) a 0.46-fold significant decrease in 
migration distance was measured. Both the original U251 
cells and the recombinant cell line with inducible expres-
sion of the EmGFP-miR-neg control served as reference 
and revealed no difference in migration distance upon 
induction with Doxycycline (Fig. 4j–o).
Discussion
The overall aim of this study was to identify deregulated 
potentially targetable miRNAs in migrating GBM cells. 
For this purpose, a newly established serum-free migra-
tion assay, presumably preserving the stem cell phenotype 
better than migration assays relying on serum, was used. 
We identified 30 miRNAs being deregulated in the migrat-
ing cells. MiR-1227 was identified as upregulated in the 
migrating cells and induced overexpression resulted in a 
Table 1  MicroRNA profiling of non-migrating and correspondingly 
migrating GBM cells from five GBM spheroid cultures (T78, T86, 
T87, T111 and T113)
The fold changes represent the average of all five cultures and are 
listed for the 30 deregulated miRNAs identified
Upregulated Downregulated
miR name FC P value miR Name FC P value
miR-1227 2.61 0.00295752 miR-19b −1.19 0.00373486
miR-483-5p 2.44 0.00045556 miR-19a −1.38 0.0022409
miR-886-3p 2.24 0.0002296 miR-21 −1.52 0.00301401
miR-455-3p 1.71 0.00172537 miR-598 −1.60 0.00625604
miR-19b-1* 1.62 0.00640601 miR-153 −1.62 0.00179931
miR-886-5p 1.61 0.00836716 miR-29a −1.65 8.5462E-07
miR-92a-1* 1.53 0.00448481 miR-29a* −1.69 0.00288156
miR-491 1.47 0.00095984 miR-422a −1.73 0.0031213
miR-423-5p 1.45 0.00046269 miR-424 −1.75 0.00019871
miR-181a 1.32 0.00092756 miR-374a* −1.82 0.00257081
miR-149 1.27 0.00330589 miR-340 −1.96 7.5167E-06
miR-25 1.26 0.0062177 miR-362-3p −2.02 0.00598894
miR-17 1.19 0.00846355 miR-590-5p −2.22 1.0611E-05
miR-210 −2.36 7.0884E-05
miR-29b −3.46 1.2505E-05
miR-32 −4.20 1.2091E-08
miR-222* −4.35 0.00090445
Fig. 3  qPCR results on recombinant U251 cell lines with conditional 
expression of miR-32, miR-222 and miR-1227 constructs. Results 
obtained both with un-induced and (doxycycline) induced expres-
sion of the miRNAs. Endogenous miR-16 was used as reference. All 
miRNA constructs were significantly upregulated after induction with 
Doxycline. MiR-1227 was upregulated 2.4 fold, mir-32 2.8 fold and 
miR-222 3.78 fold. Data are shown as means ± SEM, n = 4, compari-
sons were made with student’s t-test. ***P < 0.001
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Fig. 4  Migration assay over 48  h with four recombinant U251 cell 
lines (miR-1227, miR-32, miR-222, miR-control) and the original 
U251 cell line. MiRNA overexpression was induced with doxycy-
cline. MiR-1227 revealed a non-significant increase in migration 
after overexpression. MiR-32 and miR-222 revealed a significantly 
impaired migration after overexpression. Both the recombinant 
U251 with the miR-control construct and the original U251 cell line 
showed no difference in migration upon addition of doxycycline. 
Data are shown as means ± SEM, n = 12, comparisons were made 
with student’s t-test. ***P < 0.001. Scale bar 100 µm
52 J Neurooncol (2017) 132:45–54
1 3
non-significant increased migration distance after 48  h. 
MiR-32 and miR-222 were both downregulated in migrat-
ing GBM tumor cells compared to corresponding sphe-
roids. Experimental upregulation of these two miRNAs sig-
nificantly depressed migration.
We used patient-derived GBM spheroid cultures 
for miRNA profiling. The profiling was performed on 
migrating cells and corresponding spheroids in five differ-
ent cultures, three previously established in our group and 
two established during this study. It strengthens the results 
that the cultures were patient-derived compared to results 
obtained by profiling commercial cell lines like U87MG 
[25]. Several groups including our group, have published 
that U87MG is unable to migrate in an orthotopic xeno-
graft model [26], which is in line with what we find in our 
migration assay. Since we performed the miRNA profiling 
on cells maintained in a serum-free migration assay, the 
changes in miRNAs did not reflect a change due to fetal 
calf serum induced de-differentiation [27, 28]. However, 
although our assay may reflect the in vivo situation better 
by avoiding serum, our results need validation. Different 
serum-free in  vitro migration systems exist, i.e. the sphe-
roid-brain-slice culture migration model [29, 30]. However, 
the spheroid-brain-slice culture migration model requires 
combined culturing of a mouse or rat brain slice with GBM 
tumor cells. This makes it challenging to isolate migrat-
ing as well as non-migrating GBM tumor cells for analysis 
without contamination with brain slice derived rat or mice 
cells.
In this study miR-32 was identified as downregulated in 
the migrating GBM cells and experimental overexpression 
lead to decreased migration in vitro. No other studies have 
so far evaluated miR-32 expression in relation to migration 
in GBMs. Suh et  al. reported that miR-32 overexpression 
inhibited proliferation and growth in GBMs [31]. In that 
study, a miR-32 containing construct was transfected into 
the commercial cell line U87MG and orthotopic in  vivo 
experiments revealed a significantly reduced tumor volume 
as well as prolonged survival upon overexpression. MiR-32 
was found to result in p53 accumulation by directly target-
ing Mdm2 and TSC1, which are negative regulators of p53 
and the mTOR (mammalian target of rapamycin) pathway, 
respectively, leading to inhibition of cellular proliferation. 
These mechanisms may also be involved in the decreased 
migration observed in our study. However, the effects of 
miR-32 appear to be different in different cancers. In liver 
cancer miR-32 overexpression appeared to be associated 
with both increased proliferation and migration [32] and 
increased migration was also found upon overexpression in 
colorectal cancer [33].
MiR-222 has been reported to be upregulated in glio-
mas [34–36] and the expression increases with higher 
WHO grade [35]. Overexpression has been associated 
with increased migration whereas inhibition of miR-222 
reduced migration [34, 35]. Different mRNA targets have 
been reported where Yang et al. and Zhang et al. found the 
mRNA target to be within the tissue inhibitor of metallo-
proteinases (TIMP)-family, (TIMP2 [34], TIMP3 [35]), 
whereas Quintaville et al. found the target to be the phos-
phate protein PTPµ [36]. All three studies used either 
scratch and/or transwell migration assays in the presence of 
fetal calf serum. In contrast, by using a serum-free migra-
tion assay, we found that the expression of miR-222 was 
downregulated in migrating cells compared to correspond-
ing spheroids, and that overexpression of miR-222 led to 
diminished migration. Use of fetal calf serum, a multicom-
ponent strong chemoattractant, is the most likely explana-
tion for different results after overexpression of miR-222. In 
addition to this, the studies where fetal calf serum was used 
also used monolayer cultures, whereas we used spheroid 
cultures with three dimensional interactions between cells. 
Searching on miR-222 using miRConnect 2 [37], identi-
fies among other mechanistically associated genes TIMPs 
and Insulin-like growth factor binding protein 6 (IGFBP6) 
with known functional roles in tumor cell migration and 
invasion. Expression of these and related genes may easily 
depend on culture medium and a two dimensional versus 
three dimensional culture setting.
Out of the three most deregulated miRNAs, we identi-
fied miR-1227 to be 2.8-fold overexpressed in the migrat-
ing cells. Upon overexpression of miR-1227, we observed 
a non-significant increase in migration. The lack of sig-
nificance may be explained by a further increase in migra-
tion distance being unattainable, although a higher number 
of experiments might support the results. No comparable 
studies in GBMs identifying miR-1227 as overexpressed 
in the migrating cell compartment exist [38] and miR-
1227 has not previously been identified to have an effect 
on migration in gliomas. Supporting a more general role of 
miR-1227 in different cancers high levels of miR-1227 have 
also been associated with increased migration in prostate 
cancer [39], where human prostatic epithelial RWPE-2-de-
rived oncosomes containing miR-1227 seemed to enhance 
migration of cancer-associated fibroblasts.
The heterogeneity in gliomas has been displayed in sev-
eral studies [40] and four subtypes have been described 
by Verhaak et  al. [41]. The five different GBM spheroid 
cultures used in this study have been subtyped with two 
mesenchymal (T78, T111), two classical (T86, T113) and 
one proneural (T87) subtype identified [17]. In line with 
the genetic heterogeneity known to be present in gliomas 
[40], miRNA heterogeneity also exists [42, 43]. This partly 
explains the isolated miRNA clustering of the T87 spheroid 
culture data with both migrating and non-migrating. Appar-
ently these two populations of T87 cells are more similar 
than different migrating groups or the different groups of 
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spheroids. Therefore, future miRNA profiling, or any other 
profiling studies in GBMs, should be considered to also 
include GBM subtype in the analysis.
Conclusion
In our novel serum-free migration assay-based study we 
discovered 30 different miRNAs to be deregulated in 
migrating cells compared to corresponding spheroids using 
five GBM spheroid cultures. Both the miRNA profiling 
and the functional validation suggested that MiR-1227 may 
be associated with increased migration and miR-32 and 
miR-222 with decreased migration of glioma cells. These 
miRNAs may represent potential novel targets in migrating 
glioma cells having a stem cell phenotype.
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